Bengaluru, December 31, 2024: Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), a leading global pharmaceutical company, has achieved a significant milestone by receiving Good Manufacturing Practices (GMP) certification from the Ministry of Health of Moldova for its antibiotic-carbapenem manufacturing facility. The certification follows a comprehensive inspection conducted in October 2024, with final approval granted in December 2024.

Carbapenems, recognized as a class of broad-spectrum antibiotics, are instrumental in treating severe infections. This certification further solidifies Venus Remedies’ reputation as a global leader in providing reliable and high-quality antibiotics.

“In 2024, Venus Remedies established itself as one of the top five pharmaceutical exporters from India to Moldova. The GMP certification for Venus Remedies’ facility is expected to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026. With this certification, we are now well-positioned to further extend our presence in the Eastern European market,” said Mr. Saransh Chaudhary, President, Global Critical Care, Venus Remedies, and CEO, Venus Medicine Research Centre.  

The European antibiotics market was valued at $11,561.2 million in 2019 and is projected to reach $13,529.8 million by 2027, growing at a CAGR of 1.9% from 2020 to 2027.

Specifically, the Europe carbapenem market generated revenue of USD 1,061.4 million in 2022 and is expected to grow at a CAGR of 4% from 2023 to 2030.

In Moldova, the pharmaceutical market is witnessing promising growth. It is expected to demonstrate an annual growth rate (CAGR 2024–2029) of 3.22%, reaching a market volume of $83.32 million by 2029. Additionally, the growing availability of generic drugs has made medications more affordable, while the rise of online pharmacies has improved accessibility for consumers.

Aditi Chaudhary, President of International Business at Venus Remedies, said, “Antibiotics, along with oncology and hormones, rank among the leading therapy areas for Indian pharmaceutical exports to Moldova. This approval will ensure access to effective and dependable antibiotics for healthcare providers and patients in the country.”

These achievements underscore Venus Remedies’ commitment to delivering high-quality healthcare solutions globally while strengthening its foothold in high-growth markets like Eastern Europe.

The post VENUS REMEDIES SECURES GMP CERTIFICATION FROM MOLDOVA MINISTRY OF HEALTH FOR ANTIBIOTIC-CARBAPENEM FACILITY  appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.

 Mumbai, October 12, 2023: Venus Remedies Limited, a leading pharmaceutical company known for its commitment to innovation and healthcare excellence, is proud to announce the successful launch of Elores in Ecuador. This significant expansion follows the earlier launches of Elores in  countries like Saudi Arabia, Myanmar, Oman, Tanzania, Ethiopia, and India, marking a momentous stride in the company’s global growth.  Additionally, the dossier has also been submitted in around 15 countries for getting the marketing authorisations.

Elores, a cutting-edge antibiotic formulation, has been developed to combat multi-drug-resistant infections, making it a ground breaking addition to Venus Remedies Limited’s product portfolio. It is a novel patented Antibiotic Adjuvant Entity containing a beta-lactam antibiotic, a beta-lactamase inhibitor, and an Antibiotic Resistance Breaker (ARB) that work synergistically to rescue antibiotic activity and suppress the emergence of resistance against the antibiotic. With its proven efficacy against a wide range of bacteria, Elores is set to revolutionise the treatment of infections and enhance the quality of healthcare in Ecuador.

“We are redefining the scope of antibiotics through innovative R&D. Elores, a reliable carbapenem sparer, is the result of more than a decade of research wherein multiple studies were performed to elucidate the role of ARBs as one of the prospective solutions to save the life of existing antibiotics. Elores was our response to the problem of AMR, and it has been very satisfying to see the difference that it is making in the lives of patients,” expressed Saransh Chaudhary, CEO, Venus Medicine Research Centre.

The eighth largest economy in Latin America, Ecuador witnessed a CAGR of 5.5% from 2015 to 2020, thereby becoming a US$1.6-billion pharmaceutical market. The Ecuador antibiotics market is majorly dependent on imports from India. Ecuador had imported antibiotics worth US $3.5 million in 2022. The launch of Elores in Ecuador is expected to open the doors for the entry of the novel antibiotic adjuvant entity in other important Latin American countries (LAC) as well.

With alarming AMR resistance rates of as high as 84% for some of the deadly pathogens, Ecuador suffers a great deal of life loss from these bacteria. Exhibiting a similar situation across Latin America, the growth of such pathogens and the spread of resulting infectious diseases are bound to have a far-reaching impact.

Commenting on the launch, Aditi K Chaudhary, President, International Business, Venus Remedies, stated, “We are thrilled to introduce Elores to the people of Ecuador. We stand resolute in our commitment to developing innovative solutions to combat antibiotic resistance and improve patient outcomes. With Elores, we aim to provide a reliable and effective solution to healthcare professionals in Ecuador, enabling them to better serve their patients.”

Elores has garnered widespread acclaim for its unique combination of antibiotics that work synergistically to combat even the most challenging infections. This launch is part of Venus Remedies Limited’s ongoing mission to address the global health crisis of antibiotic resistance. Elores was declared the best innovation and received a gold medal under the India Innovation Growth Program in the year 2013.

About Venus Remedies

Panchkula-based Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) is among the 10 leading fixed-dosage injectable manufacturers in the world. Having a commercial presence in 70+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices. Its manufacturing units are certified for ISO 9001, ISO 14001, ISO 18001 and OHSAS. The company has also been approved by European- GMP, WHO-GMP and Latin American GMP (INVIMA), among others. Ranked 107th in Asia and among the world’s 500 largest pharmaceutical manufacturing companies, Venus Remedies has been granted more than 130 patents worldwide and having more than 125 registered trademarks and 25 copyrights for its innovative research products.

The post Venus Remedies Limited Expands Global Reach with the Launch of Elores in Ecuador appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.

The event hosted in commemoration of Rajkiya Shramik Divas celebrated the blood, sweat and tears invested by the diligent workers of Venus Remedies day in and day out. The Honourable Chief Minister of Haryana, Shri Manohar Lal Khattar congratulated the workers and called upon them to live in harmony with each other, thereby righteously celebrating Lord Vishwakarma Day, also called the State Labour Day.

The Chief Minister presented the award, emphasising the outstanding progress Venus Remedies has made in establishing an atmosphere where everyone feels secure, valued and empowered. This achievement reflects the collective hard work, dedication and unity of the entire Venus Remedies family.

The Best Working Conditions Award substantiates the company’s dedication to fostering a safe and nurturing environment for its employees. It acknowledges the persistent efforts in accident prevention and the promotion of welfare and health activities for its workforce, a “no-compromise” principle adopted and abided by the company.

In expressing gratitude for this achievement, Venus Remedies extended heartfelt thanks to each and every member of its team whose dedication, commitment and passion played a pivotal role in securing this distinguished recognition. The company acknowledged that this success would not have been possible without the relentless efforts of its employees.

Venus Remedies Limited remains immensely grateful for the hard work and unwavering support of its team members, and it is committed to strive for excellence. The company’s goal is to create an even safer, healthier and happier workplace for all, solidifying its position as a leader in the pharmaceutical industry.

“Our employees are our greatest assets. We believe that the true measure of our success lies in the well-being and safety of our employees. This award reaffirms our commitment to create a workplace where every individual thrives, and we, as an organisation, will continue to sustain it,” said Venus Remedies Executive Director Akshansh Chaudhary.

Venus Remedies Limited remains committed to its vision of creating a safer, healthier and happier workplace for all. The company’s achievement of the Best Working Conditions Award 2022 serves as a testament to its dedication to the occupational well-being of its employees and its commitment to excellence.

About Venus Remedies

Panchkula-based Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) is among the 10 leading fixed-dosage injectable manufacturers in the world. Having a commercial presence in 70+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices. Its manufacturing units are certified for ISO 9001, ISO 14001, ISO 18001 and OHSAS. The company has also been approved by European- GMP, WHO-GMP and Latin American GMP (INVIMA), among others. Ranked 107th in Asia and among the world’s 500 largest pharmaceutical manufacturing companies, Venus Remedies has been granted more than 130 patents worldwide and having more than 125 registered trademarks and 25 copyrights for its innovative research products.

The post Venus Remedies Limited Honoured with Best Working Conditions Award 2022 appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.